

Semaglutide (Wegovy®) for Weight Management SWL Position statement (Updated April 2024)

Prescribing of Semaglutide (Wegovy®) for weight loss is restricted to tier 3 and 4 weight management services at St George's hospital, in line with the criteria set and therefore should not be issued in primary care.

On 8 March 2023, the National Institute for Health and Care Excellence (NICE) published [guidance recommendations \[TA875\] on semaglutide for managing overweight and obesity](#) within specialist weight management services (including Tier 3 and 4), in line with specific criteria.

At the time of the NICE publication, Wegovy®, was not commercially available for NHS use in the UK. From September 2023, Novo Nordisk, the manufacturer of Wegovy® confirmed supplies would be made available to the NHS a controlled and limited launch.

SWL ICB in conjunction with our locally commissioned weight loss specialist service has now refreshed the existing weight management pathways and referral guidelines to incorporate Wegovy® alongside the prescribing of Liraglutide (Saxenda®).

The prescribing of both Wegovy® and Saxenda® are restricted to tier 3 and 4 weight management services at St George's Hospital, in line with [NICE TA875](#) and [TA664](#) respectively.

Prescriptions of all liraglutide or semaglutide-containing formulations for the management of weight **should not** be issued in primary care.

Clinicians can access the local tier 3 and 4 weight management referral form and pathway for Wegovy® and liraglutide via DXS.

Document History

Version 1.1 (accessibility applied)

Author: SWL ICB Medicines Optimisation Team

Approved by: SWL Integrated Medicines Optimisation Committee (IMOC)

Approval Date: April 2024

Review Dates April 2026